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Abstract
Background: Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited disease. It is
relatively recent that type 2C was identified as a separate group solely presenting with
pheochromocytomas. As an illustration, an interesting case is presented of a pregnant woman with
refractory hypertension. It proved to be the first manifestation of bilateral pheochromocytomas.
The family history may indicate the diagnosis, but only identification of a germ line mutation in the
DNA of a patient will confirm carriership.
Case presentation: A 27 year pregnant patient with intra uterine growth retardation presented
with hypertension and pre-eclampsia. Magnetic resonance imaging revealed bilateral adrenal
pheochromocytoma. She underwent laparoscopic adrenelectomy and a missense mutation
(Gly93Ser) in exon 1 of the VHL gene on chromosome 3 (p25 – p26) was shown in the patient,
her father and her daughter confirming the diagnosis of VHL.
Conclusion: In almost all VHL families molecular genetic analysis of DNA will demonstrate an
inherited mutation. Because of the involvement in several organs, periodic clinical evaluation should
take place in a well coordinated, multidisciplinary setting. VHL disease can be classified into several
subtypes. VHL type 2C patients present with pheochromocytomas without evidence of
haemangioblastomas in the central nervous system and/or retina and a low risk of renal cell
carcinoma. Therefore, in such families, periodic clinical screening can be focussed on
pheochromocytomas.
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Background
A pheochromocytoma is a common tumour in patients
with von Hippel-Lindau disease (VHL disease). VHL dis-
ease is an autosomal, dominant inherited tumour syn-
drome with an estimated prevalence of 2–3 patients per
100,000 persons. VHL is characterised by highly vascular-
ised tumours in different organs.
Here, we describe a patient with VHL type 2C who was
referred to our hospital with bilateral pheochromocyto-
mas during pregnancy. DNA-analysis of the VHL-gene
revealed that several family members had the same muta-
tion in the VHL gene.
Case presentation
A 27 year old pregnant woman, the index patient, was
referred to the obstetric department of our University Med-
ical Centre with hypertension and pre-eclampsia at 26
weeks. Ultrasonography showed intra-uterine growth retar-
dation. History showed that the patient's father had under-
gone a resection of the right adrenal gland at the age of 48
because of a pheochromocytoma. Clinical evaluation of
the index patient with magnetic resonance imaging (MRI)
revealed bilateral adrenal pheochromocytomas, the right
tumour being 4 centimetres and the left 1 centimetre in
diameter. Twenty-four hours urine analysis showed a creat-
inin of 8.8 mmol/24 hours (reference 9–18 mmol/24
hours), metanephrines 21.6 μmol/24 hours (ref:<1–8
μmol/24 hours), VMA 64 μmol/24 hours (8–36 μmol/24
hours), free adrenaline 146 nmol/24 hours, free noradren-
aline 4850 nmol/24 hours (90–470 nmol/24 hours) and
free dopamine 4450 nmol/24 hours (420–2600 nmol/24
hours). She had no café-au-lait spots. She received alpha-
adrenergic receptor blockade (doxazosine 160 mg), cal-
cium channel blockers (nifedipine 30 mg) and beta-recep-
tor blockade (metoprolol 100 mg) one week later. At 28
weeks a Caesarean section was performed due to pre-
eclampsia and a daughter was born weighing 745 grams
with a length of 33 cm. Her head circumference measured
23 cm. During this procedure the right adrenal gland was
removed through a subcostal incision without any intra-
operative complications.
The obstetrician referred the mother to the endocrinolo-
gist. Additional family history demonstrated that the
patient's paternal grandmother had died at the age of 42
as a result of a stroke. It remains unclear whether she suf-
fered from a pheochromocytoma. The index patient's
grandmother's brother also died from of a stroke at the
age of 57. Both patients may have had a pheochromocy-
toma since cerebrovascular accidents are known compli-
cations. Another theory is they both suffered from
cerebellar haemangioblastomas. However, these cerebel-
lar neoplasms more often present with cerebellar signs
and symptoms as headache, nausea and vomiting, dizzi-
ness, blurred vision, nystagmus, ataxia, intention tremors,
coordination deficits and at a later stage herniation of the
cerebellum, oedema and death. This suggests that pheo-
chromocytomas would be the more plausible explana-
tion.
Three months later the patient underwent an uncompli-
cated laparoscopic adrenalectomy for the left pheochro-
mocytoma. Subsequently, she was treated adequately
with hydrocortisone, mineralocorticoids and dehydroepi-
androsterone.
The differential diagnosis for the index patient focussed
on VHL disease and multiple endocrine neoplasia type 2.
DNA analysis, did not demonstrate a RET proto-oncogene
mutation. Later, a missense mutation (Gly93Ser) in exon
1 of the VHL gene on chromosome 3 (p25 – p26) was
shown in the patient, her father and her daughter. The
diagnosis of VHL disease was now proven based on the
positive family history for pheochromocytoma and the
mutation in the VHL gene. Further diagnostic work-up
revealed two small lesions suspicious for inactive angi-
omas on the right retina in the index patient and the left
without any abnormalities.
The family had many questions concerning the risks of the
daughter having VHL disease and was referred to the
Department of Clinical Genetics for counselling.
Additional ultrasonography in the father showed epididy-
mal cysts on the left side and bilateral renal cysts. An MRI
of the brain and spinal cord showed no signs of haeman-
gioblastomas and examination of the eyes no retinal hae-
mangioblastomas.
The family tree of the family is depicted in Figure 1. The
sister of our index patient did not inherit the family's
mutation. The patient, her father, and daughter remain in
a periodical screening program for VHL disease for early
detection of other VHL associated tumours, but especially
pheochromocytomas.
Discussion
About 12–24% of all pheochromocytomas are hereditary
and occur as a feature of familial syndromes  [1-8]. Bilat-
eral adrenal pheochromocytomas are often part of a
familial tumour syndrome most likely being multiple
endocrine neoplasia syndrome type 2 (MEN 2) or von
Hippel-Lindau syndrome (VHL). Bilateral extra-adrenal
pheochromocytomas often occur in paraganglioma (PGL)
syndromes[9]. In neurofibromatosis type 1 (NF1) adrenal
pheochromocytomas occur in nearly 1% and bilateral
localization is an exception.World Journal of Surgical Oncology 2007, 5:112 http://www.wjso.com/content/5/1/112
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In patients with at least one typical VHL-associated
tumour, a clinical diagnosis of VHL disease can be made
if a positive family history of a typical VHL-associated
tumour exists which was the case in the reported family.
Typical tumours in VHL disease are haemangioblastomas
of the retina, cerebellum and medulla, renal cell carcino-
mas (RCC), and pheochromocytomas. Other VHL
tumours are cysts with adenomas in the kidneys, pancre-
atic islets, epididymis, ligamentum latum, fallopian tubes
and ovaries, and endolymphatic sac tumours [10,11]. A
wide range of disease and age manifestations exists
between families and within families[11,12].
VHL disease is classified into four subtypes, type 1 without
pheochromocytoma, and type 2A, B and C having risk of
development of pheochromocytoma. Patients with type
2A have a low risk of RCC while type 2B patients have a
high risk of RCC. VHL type 2C confers an increased risk of
pheochromocytomas without other manifestations of the
disease. In type 1 families deletions in the VHL gene are
often detected, whereas in type 2 disease missense muta-
tions are most often encountered. It is presumed that the
genotype-phenotype correlation in VHL disease is a reflec-
tion of the altered pVHL function caused by a mutation.
Genotype-phenotype correlation for VHL disease and
possible responsible pathophysiological mechanisms are
shown in Table 1[10,11,13-15].
This family appeared to have only pheochromocytomas
as part of the VHL syndrome and has therefore been clas-
sified as VHL type 2C. Renal cysts and epididymal cysts
often occur in the normal population and can not be
regarded as pathognomonical for VHL disease.
Molecular genetics
Carriership of a germline mutation in the Von Hippel-
Lindau gene predisposes to the VHL-disease. The VHL
gene is a relatively small gene of approximately 14.500
basepairs (bp) of genomic DNA. It is a tumour suppressor
gene and a tumour cell develops when inactivation of
both copies of the VHL gene occurs.
The normal VHL gene produces two proteins with similar
biochemical and functional behaviour, both are
addressed as pVHL. Depending on the specific tissue, they
are functioning as co-activator or co-repressor. The VHL
protein (pVHL) is widely expressed in normal human tis-
sues, not only confounded to organs at risk for VHL dis-
ease [10,16]. In human embryos, pVHL is expressed in all
three germ layers with a strong expression in the central
nervous system, kidneys, testes and lungs[17]. pVHL
forms a complex with different proteins including tran-
scription factors Elongin B and C. That binding site is
often affected in VHL disease. pVHL inhibits transcription
elongation. The VHL protein has been shown to play an
important role in the degradation of the transcription fac-
tor hypoxia-inducible factor 1α (HIF-1α). When HIF-1α is
not properly degraded, an overproduction of vascular
endothelial growth factor (VEGF) occurs. Cells act as if
they are short of oxygen and as a result excessive blood
vessel formation develops [18,19]. Both haemangioma
and renal cell carcinoma show an abundance of blood
vessels which is mainly driven by VEGF overproduction
[20]. A strong correlation between overproduction of
VEGF mRNA and hypoxia is a common characteristic in
human malignancies. While haemangiomas and renal cell
carcinomas are highly vascularised, the vascularisation of
VHL pheochromocytomas is less prominent.
pedigree of the family Figure 1
pedigree of the family.
Index case; bilateral pheochromocytoma
Index patient’s grandmother and grandmother’s brother died as a 
consequence of a cerebral vascular incident, at resp, the age of 42 and 57. 
They probably both developed these due to pheochromocytomas caused by 
VHL disease.
Pheochromocytoma right adrenal gland; 
Epididymal cysts left sidet; bilateral renal 
cysts. 
Index patient’s daughter tested positive for 
VHL. World Journal of Surgical Oncology 2007, 5:112 http://www.wjso.com/content/5/1/112
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In patients with a germline mutation in the VHL gene
causing its inactivation, a tumour cell can develop when
the wild type allele is lost. In most VHL-disease related
tumours, this "loss of heterozygosity" has been demon-
strated [21]. There is a diverse collection of mutations
throughout the VHL-gene. In forty percent a missense
mutation is found.
In VHL disease, pheochromocytomas are solely found in
type 2 caused by certain missense mutations, leading to a
change in one single amino acid [22]. It is hypothesized
that another tumourigenic mechanism exists for missense
mutations in VHL type 2C (gain of function) as compared
to missense mutations in VHL type 1 (loss of function). It
is still unclear why two apparently opposing effects are
caused by one and the same missense mutation, leading
to different types of tumours in VHL type 2A and 2B
[14,15].
From in vivo experiments in mice, Hoffmann et al., has
described a group of VHL type 2C mutants which all
retained the ability to interact with HIF and to down reg-
ulate HIF target genes when reintroduced into pVHL
defective tumour cells. This provides a biologically con-
ceivable mechanism to account for the low risk of hae-
mangioblastomas associated with these mutants.
Furthermore all type 2C mutants showed decreased
fibronectin binding which is required for extracellular
matrix formation. pVHL fulfills this function by direct
binding to fibronectin.' This suggests that decreased
fibronectin binding is important for pheochromocytoma
development.
Gain of function in VHL2C may induce tumourigenesis of
chromaffin cells directly.
It would be interesting to investigate whether this effect
also plays a role in pheochromocytoma development in
VHL type 2A and 2B [13-15].
In the Human Gene Mutation Database 6 previously
reported mutations at the 93 codon are listed. Only one
involved the Gly93Ser mutation (UMD 140) and was
reported by Zbar [23]. The related phenotype is associated
with a high risk of pheochromocyomas. It is unclear
whether this phenotype solely involves pheochromocyto-
mas. The other mutations are Gly93Asp.
DNA analysis
In patients with familial pheochromocytoma screening
for gene mutations in the RET, VHL, SDHB and SDHD
gene is recommended since different familial syndromes
can be revealed.
In one hundred percent of families with a classical presen-
tation of more than one affected family member or a clas-
sic sporadic patient with multiple VHL-related tumours, a
germline mutation is found in the VHL-gene [6,24,25].
These germline mutations are not solely found in classical
families, but are also found in patients with a typical VHL
tumour, lacking a positive family history. In these cases
there are several possibilities. Either the family history is
not sufficient or cannot be taken, or one of the parents is
a carrier but has no expression of the disease, the possibil-
ity of non-paternity or it is a 'de novo' mutation. De novo
mutations occur in 20% of the identified germline muta-
tion carriers.
In all patients suspected of bearing VHL disease DNA
analysis is indicated. Evidence of a VHL germline muta-
tion is necessary for confirmation of the clinical diagnosis
Table 1: Genotype-phenotype correlation for VHL disease and possible responsible pathofysiological mechanisms.
Type 
VHL
Type of VHL gene germline mutation Retinal HAB CNS HAB RCC PHEO Mechanisms for VHL mediated tumorigenesis
1 Missense + + + - Loss of function (i.e. HIF decreased)
Microdeletions
Insertions
Splice site
Nonsense
Large deletions
2A Missense + + - + Loss of function (HAB) (i.e. HIF decreased)
Gain of function (PHEO) Fibronectin binding decreased
2B Missense + + + + Loss of function (HAB + RCC) (i.e. HIF decreased)
Gain of function (PHEO) Fibronectin binding decreased
2C Missense - - - + Gain of function (PHEO) Fibronectin binding decreased
VHL: Von Hippel-Lindau, HAB: haemangioblastoma, CNS: central nervous system, RCC: renal cell carcinoma, PHEO: pheochromocytoma, HIF: 
hypoxia-inducible factor; +: tumour present, -: no tumourWorld Journal of Surgical Oncology 2007, 5:112 http://www.wjso.com/content/5/1/112
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and or presymptomatic diagnostic evaluation of family
members.
Periodical clinical evaluation
Four categories of patients with VHL disease are eligible
for periodical clinical evaluation:
1) carriers of a VHL-gene germline mutation 2) first and
second degree family members in a VHL family with no
known germline mutation, 3) first and second degree
family members of patients who decline DNA analysis
and 4) patients with a typical VHL tumour without a
germline mutation, but with a strong suspicion of heredi-
tary tumours. Because of the involvement of multiple
organs in VHL disease, periodical clinical evaluation
should take place in a well coordinated, multidisciplinary
setting. Although evidence exists for a genotype-pheno-
type correlation (table 1) these have limited consequences
for follow-up. In VHL type 1, screening for pheochromo-
cytomas could be less intensive than in the presented fam-
ily. In type VHL 2C at least annual measurement of
catecholamines and metabolites in 24 hours-excreted
urine is indicated [26,27].
Conclusion
The near fatal outcome for both mother and child as
described in this report is a clear reminder of the impor-
tance of careful family history taking in hypertensive preg-
nant patients. The significance of genetic testing in
patients presenting with bilateral pheochromocytoma is
affirmed by this case with pheochromocytomas as part of
VHL disease.
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